Managing acute pain with inhaled methoxyflurane in non-cancer patients: a review of the latest evidence

Partha Patel,Carmen F Al Aadah,Lelia F Al Aadah,Henry C Y Wong,Shing Fung Lee,Muna Alkhaifi,Joel Finkelstein,Leon Rivlin
DOI: https://doi.org/10.1097/SPC.0000000000000726
2024-12-01
Abstract:Purpose of the review: Penthrox® (inhaled methoxyflurane, IMF) is an inhaled analgesic used for the treatment of moderate-to-severe acute pain. It has various advantages including the capacity for being self-administered in the presence of healthcare providers (HCPs), rapid onset and offset, and having documented evidence for minimal adverse events post-use. In a variety of non-oncological settings such as pre-hospital transport and minor outpatient procedures, amongst others, IMF has significantly reduced acute pain. As IMF has the capacity to provide appreciable pain relief but is not as widely used as other acute analgesics (i.e., opioids), this review of past and current literature hopes to explore the impact of inhaled IMF on patient outcomes, procedures where it could be used, and to inform readers about this compound. Recent findings: In general, patients who used IMF had decreased pain, improved psychosocial factors (i.e., reduced anxiety, improved satisfaction), and minimal adverse events thereby being concluded as safe for use. Summary: Future use in remote medical interventions such as military contexts, in emergency room settings, and administration under the supervision of first responders such as non-paramedic and non-HCPs further broadens the scope of settings where IMF can meaningfully be implemented.
What problem does this paper attempt to address?